Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Moronecidin-like peptide** is a synthetic or naturally derived antimicrobial peptide belonging to the piscidin family, characterized by amphipathic α-helical structure and cationic properties[1][4]. It is found in various fish species, including Antarctic fishes (Notothenia coriiceps, Parachaenichthys charcoti) and is similar to moronecidin originally identified from the hybrid striped bass[2][4]. The peptide exhibits potent broad-spectrum **antibacterial** activity against both Gram-positive and Gram-negative bacteria as well as antifungal activity against *Candida albicans*, *Candida glabrata*, and *Candida tropicalis*[1][4]. The mechanism of action involves disruption of microbial cell membranes, leading to cell lysis, which is typical of antimicrobial peptides (AMPs)[1][4]. Its cytotoxicity and hemolytic activity on human cells are minimal, suggesting potential for therapeutic application against fungal infections, especially those caused by *Candida*[1][4]. Modification by C-terminal amidation increases the peptide's activity and can also increase toxicity; the non-amidated form generally exhibits lower cytotoxicity[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moronecidin-like peptide.